744208-84-2

Upstream product

• 1378531-99-7 (R)-3-((S)-1-hydroxy-2-((4-methoxybenzyl)oxy)ethyl)-3-(methylthio)dihydrofuran-2(3H)-one 
• 1378532-00-3 (3S,4S)-3-(hydroxymethyl)-5-((4-methoxybenzyl)oxy)-3-(methylthio)pentane-1,4-diol 
• 1378532-01-4 (2S,3S)-5-((tert-butyldiphenylsilyl)oxy)-3-(((tert-butyldiphenylsilyl)oxy)methyl)-1-((4-methoxybenzyl)oxy)-3-(methylthio)pentan-2-ol 
• 1378532-02-5 tert-butyl(((2R,3S)-2-(2-((tert-butyldiphenylsilyl)oxy)ethyl)-3-(((4-methoxybenzyl)oxy)methyl)oxiran-2-yl)methoxy)diphenylsilane 
• 58479-61-1 tert-butylchlorodiphenylsilane 
• 827036-25-9 C₃₈H₄₈O₃Si₂ 

Downstream Products

• 744208-86-4 C₅₉H₈₆O₆Si₂ 
• 744208-68-2 C₃₁H₄₅NO₁₀ 
• 744208-91-1 (S)-di-tert-butyl 2-((S,Z)-1-(((S)-3-(4-(but-2-yn-1-yloxy)phenyl)-1-(tert-butoxy)-1-oxopropan-2-yl)amino)-1,11-dioxooctadec-3-en-2-yl)-2-hydroxysuccinate 
• 744208-75-1 NA 808 
• 744208-85-3 C₅₆H₈₂O₆Si₂ 
• 1422543-02-9 C₅₇H₈₄O₆Si₂ 
• 1422550-02-4 C₃₁H₅₂O₈ 
• 1422550-03-5 C₃₁H₄₆O₈ 

Relevant academic research and scientific papers

Compound and Asymmetric Synthesis Reaction

A compound represented by the following General Formula (1): where R1 represents a protective group for a hydroxyl group or a hydrogen atom, and R2 represents a methyl group or an ethyl group.

Enantioselective synthesis of derivatives and structure-activity relationship study in the development of NA255 as a novel host-targeting anti-HCV agent

Hepatitis C virus (HCV) infection represents a serious health-care problem. Previously we reported the identification of NA255 from our natural products library using a HCV sub-genomic replicon cell culture system. Herein, we report how the absolute stereochemistry of NA255 was determined and an enantioselective synthetic method for NA255 derivatives was developed. The structure-activity relationship of the NA255 derivatives and rat pharmacokinetic profiles of the representative compounds are disclosed.

A direct catalytic asymmetric aldol reaction of α-sulfanyl lactones: Efficient synthesis of SPT inhibitors

Softly does it: The title reaction, catalyzed by a AgPF6/(R)- biphep-type ligand/DBU complex, is described (see scheme). This protocol gives efficient access to syn-configured α-sulfanyl-β-hydroxy lactones in a highly enantioselective manner. In one particular case, the sulfide group was stereospecifically replaced with a hydroxy group to afford an enantioenriched tertiary alcohol, which upon further manipulation led to a class of densely functionalized SPT inhibitors. Copyright

REMEDY FOR VIRAL DISEASE

The object of the present invention is to provide a pharmaceutical composition for preventing or treating viral infectious diseases. The compounds of the present invention have extremely potent anti-HCV activity and HCV growth inhibitory effects, and sinc